Alternatives to open heart surgery.

Depending on the cardiac diagnosis, alternatives may include: percutaneous coronary intervention (PCI) with drug-eluting stents for coronary disease; transcatheter aortic valve replacement (TAVR) for aortic stenosis; MitraClip or transcatheter edge-to-edge repair (TEER) for mitral regurgitation; transcatheter valve-in-valve replacement for failed bioprosthetic valves; thoracic endovascular aortic repair (TEVAR) for descending thoracic aortic disease; optimal medical therapy with guideline-directed pharmacotherapy; and structured watchful waiting with serial imaging.

For many patients with severe aortic stenosis, yes. The PARTNER 3 and Evolut Low Risk trials (both 2019) demonstrated TAVR non-inferiority to surgical AVR in low-risk patients, leading to FDA approval across all surgical risk categories. The 2020 ACC/AHA Valvular Heart Disease guidelines recommend shared Heart Team decision-making for patients aged 65-80, with TAVR generally preferred over SAVR for patients over 80 and for those with high surgical risk. Open surgery (SAVR) may still be preferred for younger patients (under 65), patients with bicuspid aortic valves, those with concomitant CABG or other valve disease, and those with anatomic features unfavorable for TAVR.

Sometimes — it depends on the coronary anatomy and patient profile. Percutaneous coronary intervention (PCI) with drug-eluting stents can replace CABG in selected patients with single-vessel or two-vessel disease and favorable anatomy. However, the FREEDOM trial (2012) showed CABG superiority in diabetic patients with multivessel disease, and the SYNTAX trial showed CABG advantage for complex three-vessel and left main coronary disease. The 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization is the canonical reference. A Heart Team review is a Class I recommendation for these decisions.

Open heart surgery may not be necessary when: (1) the cardiac pathology does not meet ACC/AHA guideline indication (e.g., asymptomatic moderate AS with preserved EF); (2) a less-invasive catheter-based alternative is appropriate (TAVR, PCI, MitraClip, TEVAR, valve-in-valve); (3) optimal medical therapy can defer or replace surgery (e.g., heart failure guideline-directed therapy); (4) watchful waiting with serial imaging is defensible (e.g., asymptomatic mitral regurgitation with preserved LV function); or (5) the patient’s frailty / comorbidity profile makes operative mortality risk prohibitively high. A dual-physician Heart Team second opinion is the way to determine which of these applies.

Optimal medical therapy (OMT) is the use of guideline-directed pharmacotherapy to treat cardiac disease without surgery. For coronary artery disease: aspirin or P2Y12 inhibitor, high-intensity statin, beta blocker (for prior MI), ACE inhibitor or ARB (for diabetes or reduced EF), and aggressive risk-factor management. For heart failure with reduced EF: ARNI (sacubitril-valsartan), beta blocker, mineralocorticoid receptor antagonist (spironolactone or eplerenone), and SGLT2 inhibitor (the four pillars of HFrEF therapy). For atrial fibrillation: anticoagulation per CHA‚‚DS‚‚-VASc score plus rate or rhythm control. OMT alone is appropriate first-line for many patients; surgery is reserved for those who fail OMT or have specific surgical indications.

Watchful waiting (serial echocardiography every 6-12 months) is safe and recommended for: asymptomatic moderate-severe aortic stenosis with preserved ejection fraction and no exercise testing abnormalities; asymptomatic moderate mitral regurgitation with preserved LV function and dimensions; asymptomatic mild-to-moderate aortic regurgitation with normal LV; and asymptomatic small ascending aortic aneurysms below the surgical threshold (typically <5.0-5.5 cm depending on body size and connective tissue status). The trigger for surgery is symptoms, LV dysfunction, or progression beyond the guideline-defined threshold.

You determine this with a dual-physician Heart Team review that evaluates your specific anatomy, risk profile, and life expectancy against the guideline indications for each alternative. WhiteGloveMD does this in 24 hours, with a written report that explicitly compares the recommended surgical procedure against each potential alternative (with the evidence base for each shown).